Clinicopathologic Factors Influencing Endoscopic Versus Surgical Approaches in Patients With T1b Gastric Carcinoma With Lymphoid Stroma.

IF 1.9 3区医学 Q3 ONCOLOGY

Journal of Surgical Oncology Pub Date : 2025-08-14 DOI:10.1002/jso.70053

Sun Mi Lee, Ji Young Kim

{"title":"Clinicopathologic Factors Influencing Endoscopic Versus Surgical Approaches in Patients With T1b Gastric Carcinoma With Lymphoid Stroma.","authors":"Sun Mi Lee, Ji Young Kim","doi":"10.1002/jso.70053","DOIUrl":null,"url":null,"abstract":"Background: Pathologic T1b (pT1b) gastric carcinoma with lymphoid stroma (GCLS) has been proposed as a potential candidate for endoscopic resection due to reported low rates of lymph node metastasis (LMN). Evaluation of the clinicopathological factors associated with the risk of LNM may lead to improved treatment options for patients with pT1b GCLS.Methods: A retrospective cohort analysis examined 102 patients with resected pT1b GCLS from 2012 to 2022. Patients with pT1b gastric adenocarcinoma (GAC) served as the control group. We investigated the clinicopathologic factors associated with the risk of LNM and potential morbidities related to endoscopic approaches in patients with T1b GCLS.Results: Of the 102 patients with pT1b GCLS, 88.2% had positive Epstein-Barr virus (EBV) tests. Tumors were located in the upper stomach in 20.6% of pT1b GCLS patients, with a median submucosal invasion depth of 1430 µm. LNM was identified in 11.8% of these patients (each, p < 0.01). In comparison, among the 143 patients with pT1b GAC, only 0.7% had positive EBV tests. Tumors were located in the upper stomach in 5.6% of these patients, with a median submucosal invasion depth of 700 µm, and 20.3% of GAC patients had LNM.Conclusions: Considering the higher rates of deeply invading submucosal tumors and of LNM, our study suggests that surgical approaches should remain the standard recommended therapy for patients with pT1b GCLS.","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.70053","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pathologic T1b (pT1b) gastric carcinoma with lymphoid stroma (GCLS) has been proposed as a potential candidate for endoscopic resection due to reported low rates of lymph node metastasis (LMN). Evaluation of the clinicopathological factors associated with the risk of LNM may lead to improved treatment options for patients with pT1b GCLS.

Methods: A retrospective cohort analysis examined 102 patients with resected pT1b GCLS from 2012 to 2022. Patients with pT1b gastric adenocarcinoma (GAC) served as the control group. We investigated the clinicopathologic factors associated with the risk of LNM and potential morbidities related to endoscopic approaches in patients with T1b GCLS.

Results: Of the 102 patients with pT1b GCLS, 88.2% had positive Epstein-Barr virus (EBV) tests. Tumors were located in the upper stomach in 20.6% of pT1b GCLS patients, with a median submucosal invasion depth of 1430 µm. LNM was identified in 11.8% of these patients (each, p < 0.01). In comparison, among the 143 patients with pT1b GAC, only 0.7% had positive EBV tests. Tumors were located in the upper stomach in 5.6% of these patients, with a median submucosal invasion depth of 700 µm, and 20.3% of GAC patients had LNM.

Conclusions: Considering the higher rates of deeply invading submucosal tumors and of LNM, our study suggests that surgical approaches should remain the standard recommended therapy for patients with pT1b GCLS.

查看原文本刊更多论文

影响T1b胃癌伴淋巴样基质患者内镜与手术入路的临床病理因素。

背景：病理性T1b （pT1b）胃癌伴淋巴样间质（GCLS）由于报道的低淋巴结转移率（LMN）已被提出作为内镜切除的潜在候选者。评估与LNM风险相关的临床病理因素可能会改善pT1b GCLS患者的治疗选择。方法：回顾性队列分析2012年至2022年102例pT1b型GCLS切除术患者。以pT1b型胃腺癌（GAC）患者为对照组。我们研究了与T1b GCLS患者的LNM风险相关的临床病理因素以及与内镜入路相关的潜在发病率。结果：102例pT1b型GCLS患者中，88.2%的患者EBV阳性。20.6%的pT1b GCLS患者肿瘤位于上胃，粘膜下浸润中位深度为1430µm。结论：考虑到深部浸润粘膜下肿瘤和LNM的发生率较高，我们的研究表明，手术方法仍应是pT1b GCLS患者的标准推荐治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Surgical Oncology 医学-外科

CiteScore

4.70

自引率

4.00%

发文量

367

审稿时长

2 months

期刊介绍： The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.